Searched for
PHARMEASY RIGHTS ISSUE
PharmEasy halves loss to Rs 2,533 crore in FY24, revenue dips 15%Mumbai-based PharmEasy, operated by API Holdings Limited, reported a net loss of Rs 2,533 crore, an improvement from the Rs 5,212 crore los...- CCI clears Ranjan Pai’s investment in PharmEasyRanjan Pai invests in PharmEasy's funding with 360 One. API Holdings board seats acquired. Rights issue resolves debt. Monthly burn reducti...
- PharmEasy’s FY23 operating revenue up 16% to Rs 6,644 crore; net loss widens 30%PharmEasy’s parent firm API Holdings cut down its advertising and promotional expenses to Rs 235 crore, less than half of what it incurred ...
- Dunzo’s survival hinges on Reliance Retail commitment to fundsAn impasse after several rounds of discussions has left Dunzo’s other investors increasingly sceptical of its chances of survival in the ab...
- 1mg overtakes PharmEasy in market share in top order changeTata 1mg had a 31% market share in September 2023 against 19% in October 2022 while PharmEasy slipped to 15% from about 33% during the same...
- PharmEasy CEO has three-year lock-in, Ranjan Pai to get three board seatsPai is also joining the board of PharmEasy and is expected to work with CEO Shah. He will retain the board seats as long as his holding doe...
- Apple flags ‘state-sponsored’ hacking, govt orders probe; inside PharmEasy’s Rs 3,500-crore rights issueThe Centre has ordered probe after opposition members, journalists received messages on their iPhones, warning them of possible ‘state-spon...
- Goldman may convert part-debt into equity in PharmEasyThe online pharmacy is also in talks to restructure debt terms ahead of rights issue; share sale set to open on September 4
- Goldman may part-convert Pharmeasy debt to equity; P2P lenders look to diversify partnershipsGoldman Sachs is likely to convert some of its loan to online pharmacy PharmEasy into equity. Buoyed by binding commitments from existing i...
- ETtech Explainer: What are down rounds and will they become the norm for Indian startups?A down round is when a privately held firm raises funds at a valuation lower than that ascribed in the previous round.
- PharmEasy valuation crash may not hit Thyrocare founder Velumani’s stakePharmEasy is faced with a steep cut in its valuation, with the new funding round pegging its shares at Rs 5 each compared to the Rs 50 per ...
- PharmEasy parent seeks shareholder nod to increase authorised share capitalThe board notified its shareholders about increasing the authorised share capital to Rs 3,500 crore (about $423.72 million), divided into 3...
- Exclusive: PharmEasy plans Rs 2,400-crore rights issue at 90% discount to repay loanMumbai-based epharmacy platform PharmEasy is likely to be valued at $500-600 million compared to the $5.6 billion valuation in 2021
- PharmEasy plans rights issue at 90% valuation cut; Amazon set to hit $8B India exportsEarlier in the day we broke the news that PharmEasy’s investors have taken control of the company as they plan a Rs 2,400 crore rights issu...
- Exclusive | Not selling Thyrocare, will cut cash burn: PharmEasy founders to boardPharmEasy’s parent API Holdings has also delayed internal plans for a potential initial public offering (IPO) to 2025, the people privy to ...
- PharmEasy floats rights issue to raise Rs 750 croreThe company's existing investors like Prosus Ventures and Temasek as well as its founders have subscribed to the issue for shares worth abo...
- PharmEasy prepares Rs 750 crore funding through convertible notesProsus Ventures, Temasek and others participate; online pharmacy reconsidering external fundraise amid funding slowdown
- PharmEasy delays IPO, targets Ebitda breakeven by next yearThe Mumbai-based firm is also stitching up a private financing round through a rights issue where company founders are expected to invest p...
- PharmEasy pulls out market listing planThe company will consider raising funds via rights issue, reported CNBC. API Holdings rights issue will have Compulsory Convertible Prefere...
- Pre-IPO bout to value PharmEasy at $6 billionTalks on with Amansa, Blackstone, OrbiMed and others as e-pharmacy eyes IPO at $7-8 billion valuation.
Load More
